The National Institute of Diabetes ...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has started a clinical studious mood comparing three treatments of mark 2 diabetes in children and teenagers. In the TODAY (Treatment Options for model 2 Diabetes in Adolescents and Youth) reflection participants will be assigned randomly to undivided of three treatment groups: metformin alone, metformin and rosiglitazone in a fixed-dose combination, and metformin plus intensive lifestyle change aimed at losing weight and increasing physical activity. generally metformin is the only oral medicine approved by the FDA to treat protoplast 2 diabetes in children. The primary goal of the trial is to determine for what cause well and for how lengthy each treatment approach controls line glucose levels. The study also will evaluate the safety of the treatments; validitys of the treatments on insulin production, insulin resistance, material substance composition, nutrition, physical activity, and aerobic fitness; risk factors for inspection kidney, nerve, and heart disease; quality of life; psychologic outcomes; the influence of individual and family behaviors onward treatment response; and cost-effectiveness of the treatments. More information about the subject of attention is available online at http://www.TODAYstudy.org.

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group